Both strategies led to the upregulation of the mechanistic target of rapamycin (mTOR) pathway and increased levels of the epigenetic regulator methyl-CpG-binding protein 2 (MeCP2), which is critically involved in neurological diseases characterized by defective plasticity, impaired cognition and intellectual disability. This evidence concerns the gene MTOR and nervous system disorder.